Tag: fasinumab

Teva, Regeneron’s fasinumab hits osteoarthritis goals

by Selina McKee | Aug 17, 2018 | News | 0

Teva and Regeneron Pharmaceuticals have unveiled positive topline results from a Phase III study assessing the safety and efficacy of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.

FDA places hold on Teva, Regeneron back pain trial

by Selina McKee | Oct 18, 2016 | News | 0

The US Food and Drug Administration has placed on hold a Phase IIb study assessing Teva and Regeneron’s investigational nerve growth factor inhibitor fasinumab for chronic low back pain.